{"id":7226,"date":"2013-06-04T08:43:42","date_gmt":"2013-06-04T12:43:42","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=7226"},"modified":"2013-06-04T08:43:42","modified_gmt":"2013-06-04T12:43:42","slug":"cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226","title":{"rendered":"Cadence Pharmaceuticals Inc. (NASDAQ:CADX) focus on commercialization of therapeutics"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 06\/04\/2013 (wallstreetpr) &#8211;\u00a0Cadence Pharmaceuticals Inc. (NASDAQ:CADX) with its primary focus on development and commercialization of therapeutics for use in common hospital setting had surged in share prices by 15.19 percent to close at $7.66 per share for the end of last trading session on Monday. This was observed to be an increase of $1.01 per share over the closing price of the shares of Cadence Pharmaceuticals Inc. (NASDAQ:CADX) on Friday.<\/p>\n<p style=\"text-align: justify;\">The shares of the pharmaceutical company had been trading in the range of $6.84 to $7.68 per share in the market on Monday. The recent surge in share prices had pushed Cadence Pharmaceuticals Inc. (NASDAQ:CADX) to hit new levels of 52 week high prices at $7.68 per share. The 52 week low price level of the company is at $2.67 per share.<\/p>\n<p style=\"text-align: justify;\">The initial product candidate being focused on developed by Cadence Pharmaceuticals Inc. (NASDAQ:CADX) is the anti infectives to be used in hospital settings. Further the company had also developed Acetavance, which is an intravenous formulation of acetaminophen. This drug is presently being marketed in Europe and is primarily used for the treatment of fever and pain.<\/p>\n<p style=\"text-align: justify;\">The shares of Cadence Pharmaceuticals Inc. (NASDAQ:CADX) had recently been heavy trading volumes and high level of surge in prices. The company had witnessed heavy trading at 1.16 million shares being exchanged on Monday, while the average trading volume of Cadence Pharmaceuticals Inc. (NASDAQ:CADX) is at 317,055 shares per day.<\/p>\n<p style=\"text-align: justify;\">Cadence Pharmaceuticals Inc. (NASDAQ:CADX) presently holds 85.80 million shares outstanding with an institutional ownership of 88 percent.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 06\/04\/2013 (wallstreetpr) &#8211;\u00a0Cadence Pharmaceuticals Inc. (NASDAQ:CADX) with its primary focus on development and commercialization of therapeutics for use in common hospital setting had [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":7227,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[1979,1980],"stock_ticker":[],"class_list":["post-7226","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-cadence-pharmaceuticals-inc-nasdaqcadx","tag-nasdaqcadx","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cadence Pharmaceuticals Inc. (NASDAQ:CADX) focus on commercialization of therapeutics - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cadence Pharmaceuticals Inc. (NASDAQ:CADX) focus on commercialization of therapeutics - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 06\/04\/2013 (wallstreetpr) &#8211;\u00a0Cadence Pharmaceuticals Inc. (NASDAQ:CADX) with its primary focus on development and commercialization of therapeutics for use in common hospital setting had [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-06-04T12:43:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/sub-n-amp.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Steve Hackney\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Steve Hackney\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226\"},\"author\":{\"name\":\"Steve Hackney\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\"},\"headline\":\"Cadence Pharmaceuticals Inc. (NASDAQ:CADX) focus on commercialization of therapeutics\",\"datePublished\":\"2013-06-04T12:43:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226\"},\"wordCount\":261,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/sub-n-amp.jpg\",\"keywords\":[\"Cadence Pharmaceuticals Inc (NASDAQ:CADX)\",\"NASDAQ:CADX\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226\",\"name\":\"Cadence Pharmaceuticals Inc. (NASDAQ:CADX) focus on commercialization of therapeutics - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/sub-n-amp.jpg\",\"datePublished\":\"2013-06-04T12:43:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/sub-n-amp.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/sub-n-amp.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cadence Pharmaceuticals Inc. (NASDAQ:CADX) focus on commercialization of therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\",\"name\":\"Steve Hackney\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"caption\":\"Steve Hackney\"},\"description\":\"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cadence Pharmaceuticals Inc. (NASDAQ:CADX) focus on commercialization of therapeutics - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226","og_locale":"en_US","og_type":"article","og_title":"Cadence Pharmaceuticals Inc. (NASDAQ:CADX) focus on commercialization of therapeutics - Wall Street PR","og_description":"Boston, MA 06\/04\/2013 (wallstreetpr) &#8211;\u00a0Cadence Pharmaceuticals Inc. (NASDAQ:CADX) with its primary focus on development and commercialization of therapeutics for use in common hospital setting had [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-06-04T12:43:42+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/sub-n-amp.jpg","type":"image\/jpeg"}],"author":"Steve Hackney","twitter_misc":{"Written by":"Steve Hackney","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226"},"author":{"name":"Steve Hackney","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867"},"headline":"Cadence Pharmaceuticals Inc. (NASDAQ:CADX) focus on commercialization of therapeutics","datePublished":"2013-06-04T12:43:42+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226"},"wordCount":261,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/sub-n-amp.jpg","keywords":["Cadence Pharmaceuticals Inc (NASDAQ:CADX)","NASDAQ:CADX"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226","url":"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226","name":"Cadence Pharmaceuticals Inc. (NASDAQ:CADX) focus on commercialization of therapeutics - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/sub-n-amp.jpg","datePublished":"2013-06-04T12:43:42+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/sub-n-amp.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/sub-n-amp.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cadence-pharmaceuticals-inc-nasdaqcadx-focus-on-commercialization-of-therapeutics-7226#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Cadence Pharmaceuticals Inc. (NASDAQ:CADX) focus on commercialization of therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867","name":"Steve Hackney","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","caption":"Steve Hackney"},"description":"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=7226"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7226\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/7227"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=7226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=7226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=7226"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=7226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}